Delta-Fly Pharma raises funds through

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on January 16, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Delta-Fly Pharma raises funds through warrant issuance

Source disclosure: January 16, 2026 Delta-Fly Pharma,Inc. [4598.T] TOKYO, Jan 16 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) raised approximately ¥719 million through the issuance of its 11th series of warrants, exercisable at an initial price of ¥246. The potential dilution rate is 24.67% percent based on the number of outstanding shares as of December 31, 2025. Funds will be allocated towards research and development activities, including clinical trials for DFP10,917+VEN c